ClinicalTrials.gg
CompletedNCT02605954Updated Nov 14, 2018Results posted

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

A Phase 3 interventional study of E/C/F/TAF and ABC/3TC in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in HIV-1 infected participants.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • HIV 1 Infection
  • HIV
  • Virologically-Suppressed
  • Antiretroviral agents
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

-infected adult participants who meet the following criteria will be given the option to participate in the study:

  • Currently receiving ABC/3TC plus a third antiretroviral (ARV) agent for ≥ 6 consecutive months preceding the screening visit. For subjects with 3 or more ART regimens, a regimen history must be provided to the Sponsor for approval. Allowed third antiretroviral agents include LPV/r, ATV+RTV, ATV+COBI (or ATV/COBI FDC), DRV+RTV, DRV + COBI (or DRV/COBI FDC) FPV + RTV, SQV + RTV, ATV (no booster), EFV, RPV, NVP, ETR, RAL or DTG
  • Documented plasma HIV-1 RNA levels \< 50 copies/mL for ≥ 6 months preceding the screening visit (measured at least twice using the same assay). In the preceding 6 months prior to screening, one episode of "blip" (HIV-1 RNA > 50 and \< 400 copies/mL) is acceptable, only if HIV-1 RNA is \< 50 copies/mL immediately before and after the "blip".
  • Plasma HIV-1 RNA \< 50 copies/mL at screening visit
  • Individuals will have no evidence of previous virologic failure on a PI+RTV or integrase strand transfer inhibitor-based regimen (with or without resistance to either class of ARV).
  • All documented historical plasma genotype(s) must not show resistance to tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC), including, but not limited to the presence of reverse transcriptase resistance mutants K65R, K70E, M184V/I, or thymidine analog associated mutations (TAMs) (TAMs are: M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R). If a historical genotype is not available or subject has 3 or more ART regimens, subject will have proviral genotype analysis prior to Day 1 to confirm absence of archived resistance to TDF or FTC.
  • Adequate renal function defined as having an estimated of ≥ 30 mL/min as calculated by (eGFR-CG)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF

    Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.

    Drug: E/C/F/TAF

  • Active comparator
    ABC/3TC+3rd Agent

    Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC. Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed.

    Drug: ABC/3TC · Drug: Third Antiretroviral Agent

Interventions

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg FDC tablets administered orally once daily

    Also known as: Genvoya®

  • DrugABC/3TC

    600/300 mg tablets administered orally once daily

    Also known as: Epzicom, Kivexa

  • DrugThird Antiretroviral Agent

    Third antiretroviral agents could include one of the following: * ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC * DRV+COBI or DRV/COBI FDC * darunavir (DRV; Prezista®) + RTV * lopinavir/ritonavir (LPV/r; Kaletra®) * atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®) * efavirenz (EFV; Sustiva®) * etravirine (ETR; Intelence®) * nevirapine (NVP; Viramune®) * rilpivirine (RPV; Edurant®) * dolutegravir (DTG; Tivicay®) * raltegravir (RAL; Isentress®) * fosamprenavir (FPV; Lexiva®) + RTV * saquinavir (SQV; Invirase®) + RTV * ATV (no booster) Drug classes: * Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV * Pharmacokinetic enhancer: COBI * Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR * Integrase inhibitors: RAL and DTG

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 12

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 12

  2. Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 48

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  3. Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline; Week 24

  4. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

07

Results

Posted Jul 13, 2018

Participant flow

Participants were enrolled at study sites in Europe and North America. The first participant was screened on 18 November 2015. The last study visit occurred on 24 Jan 2018.

Participant flow — Overall Study
MilestoneE/C/F/TAFABC/3TC+3rd Agent
Started18392
Completed17188
Not completed124
Withdrew: Adverse event51
Withdrew: Investigator's discretion10
Withdrew: Non-compliance with study drug10
Withdrew: Withdrew consent22
Withdrew: Lost to follow-up30
Withdrew: Randomized but not treated01

Outcome measures

PrimaryPercentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24
percentage of participantsE/C/F/TAFABC/3TC+3rd AgentDelayed E/C/F/TAF
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 2493.497.896.6
Statistical analysis
  • E/C/F/TAF vs ABC/3TC+3rd Agent · Fisher Exact · p = 0.15 · Difference in percentages: -4.4 · 95% CI -9.4 to 1.9
SecondaryPercentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 12

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 12
percentage of participantsE/C/F/TAFABC/3TC+3rd AgentDelayed E/C/F/TAF
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 1295.198.996.6
Statistical analysis
  • E/C/F/TAF vs ABC/3TC+3rd Agent · Fisher Exact · p = 0.17 · Difference in percentages: -3.8 · 95% CI -8.3 to 1.6
SecondaryPercentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 48

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 48
percentage of participantsE/C/F/TAF
Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 4886.9
SecondaryChange From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 24
cells/µLE/C/F/TAFABC/3TC+3rd AgentDelayed E/C/F/TAF
Change From Baseline in CD4+ Cell Count at Week 24-28 ± 161.48 ± 192.9-23 ± 201.7
Statistical analysis
  • E/C/F/TAF vs ABC/3TC+3rd Agent · ANOVA · p = 0.11 · Difference in least square mean: -36 · 95% CI -80 to 9
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLE/C/F/TAF
Change From Baseline in CD4+ Cell Count at Week 48-32 ± 147.1

Adverse events

Collected over Up to 48 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E/C/F/TAF0/183 (0%)12/183 (6.6%)71/183 (38.8%)
ABC/3TC+3rd Agent0/91 (0%)1/91 (1.1%)21/91 (23.1%)
Delayed E/C/F/TAF0/89 (0%)4/89 (4.5%)17/89 (19.1%)
All E/C/F/TAF0/272 (0%)16/272 (5.9%)88/272 (32.4%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventE/C/F/TAFABC/3TC+3rd AgentDelayed E/C/F/TAFAll E/C/F/TAF
ErysipelasInfections and infestations0/1830/911/891/272
Respiratory tract infectionInfections and infestations0/1830/911/891/272
Urinary tract infectionInfections and infestations1/1830/911/892/272
Cervical dysplasiaReproductive system and breast disorders0/1830/911/891/272
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1830/911/891/272
Deep vein thrombosisVascular disorders0/1830/911/891/272
Small intestinal obstructionGastrointestinal disorders0/1831/910/890/272
PneumoniaInfections and infestations2/1830/910/892/272
Coronary artery diseaseCardiac disorders1/1830/910/891/272
Myocardial infarctionCardiac disorders1/1830/910/891/272
Most frequent other events
Most frequent other events
EventE/C/F/TAFABC/3TC+3rd AgentDelayed E/C/F/TAFAll E/C/F/TAF
DiarrhoeaGastrointestinal disorders19/1833/914/8923/272
ArthralgiaMusculoskeletal and connective tissue disorders11/1832/918/8919/272
HeadacheNervous system disorders15/1834/914/8919/272
Vitamin D deficiencyMetabolism and nutrition disorders13/1836/910/8913/272
Back painMusculoskeletal and connective tissue disorders6/1836/912/898/272
Upper respiratory tract infectionInfections and infestations12/1835/911/8913/272
AstheniaGeneral disorders10/1831/910/8910/272

Baseline characteristics

Safety Analysis Set: participants who took at least 1 dose of E/C/F/TAF or ABC/3TC+3rd Agent (on or after Day 1).

Age, Continuous
Age, Continuous(years)E/C/F/TAFABC/3TC+3rd AgentTotal
Mean50 ± 11.649 ± 10.749 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAFABC/3TC+3rd AgentTotal
Female271744
Male15674230
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAFABC/3TC+3rd AgentTotal
Asian516
Black271542
White15075225
Other101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAFABC/3TC+3rd AgentTotal
Hispanic or Latino271643
Not Hispanic or Latino15573228
Not Permitted123
Region of Enrollment
Region of Enrollment(Participants)E/C/F/TAFABC/3TC+3rd AgentTotal
United States361955
Italy431659
United Kingdom213
France402363
Germany628
Spain563086
HIV-1 RNA Categories
HIV-1 RNA Categories(Participants)E/C/F/TAFABC/3TC+3rd AgentTotal
< 50 copies/mL17791268
50 ≥ copies/mL606
CD4 Cell Count
CD4 Cell Count(cells/µL)E/C/F/TAFABC/3TC+3rd AgentTotal
Mean701 ± 280.1753 ± 312.8718 ± 291.8
CD4 Cell Count Category
CD4 Cell Count Category(Participants)E/C/F/TAFABC/3TC+3rd AgentTotal
≥ 50 to < 200 cells/µL202
≥ 200 to < 350 cells/µL11718
≥ 350 to < 500 cells/µL301343
≥ 500 cells/µL14071211
08

Study locations

49 sites
  • Spectrum Medical Group
    Phoenix, Arizona, United States
  • Ruane Clinical Research Group
    Los Angeles, California 90036, United States
  • Capital Medical Associates, P.C.
    Washington, District of Columbia, United States
  • Georgetown University
    Washington, District of Columbia, United States
  • Gary Richmond, MD, PA, Inc.
    Fort Lauderdale, Florida, United States
  • Midway Immunology & Research Center, LLC
    Fort Pierce, Florida, United States
  • Steinhart Medical Associates dba The Kinder Medical Group
    Miami, Florida, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida, United States
  • The Positive Health Clinic, Allegheny Health Network
    Pittsburgh, Pennsylvania, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • AIDS Arms, Inc./Trinity Health & Wellness Center
    Dallas, Texas 75208, United States
  • Tarrant County ID Associates
    Fort Worth, Texas 76104, United States
  • CHU - Groupe Saint-Andre
    Bordeaux, France
  • Hopital Henri Mondor
    Creteil, France
  • Hopital Europeen Marseille
    Marseille, France
  • C.H.U. de Nantes
    Nantes, France
  • C.H.U. de NICE
    Nice, France
  • Hopital Saint Louis
    PARIS cedex 10, France
  • Hopital Saint Antoine
    Paris cedex 12, France
  • CHU Hotel Dieu
    Paris Cedex 14, France
  • Hopital Lariboisiere
    Paris, France
  • Hopital Necker les Enfants Malades
    Paris, France
  • Centre Hospitalier Gustave Dron
    Tourcoing, France
  • Epimed GmbH
    Berlin, Germany
  • Universitatsklinikum Essen
    Essen, Germany
  • ICH Study Center Hamburg
    Hamburg, Germany
  • Universitatsklinikum Hamburg-Eppendorf
    Hamburg, Germany
  • ARNAS Garibaldi - Nesima
    Catania, Italy
  • Unit Infectious Diseases - University of Catania - ARNAS Garibaldi
    Catania, Italy
  • Azienda Ospedaliera Luigi Sacco
    Milano, Italy
  • Azienda Ospedaliero Universitaria Policlinico di Modena
    Modena, Italy
  • Azienda Ospedale San Paolo
    Monza, Italy
  • Azienda Ospedaliera San Gerardo
    Monza, Italy
  • Ospedale Civile S. Spirito AUSL
    Pescara, Italy
  • Unità Operativa Complessa di Malattie Infettive
    Pescara, Italy
  • Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.
    Roma, Italy
  • Comprensorio Ospedaliero Amedeo di Savoia
    Torino, Italy
  • Dipartimento di Malattie Infettive e Tropicali
    Torino, Italy
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
  • Hospital Costa Del Sol
    Marbella, Spain
  • Hospital Reg. Univ. Carlos Haya
    Málaga, Spain
  • Hospital Clínico Universitario de Valencia (Galindo)
    Valencia, Spain
  • Hospital General Universitario de Valencia (Abril)
    Valencia, Spain
  • Hospital Alvaro Cunqueiro
    Vigo, Spain
  • Mortimer Market Centre
    London, United Kingdom
09

References and documents

Publications

  • A Gori, G Rizzardini, C Miralles, J Olalla, JM Molina, F Raffi, P Kumar, A Antinori, M Ramgopal, HJ Stellbrink, M Das, H Chu, R Ram, W Garner, SK Chuck, D Piontkowsky, R Haubrich. Switching from An Abacavir (ABC)/Lamivudine (3TC)-Based Regimen to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) is Efficacious and Safe: Week 24 Primary Analysis of a Randomized Controlled Study in Virologically-Suppressed Adults [Presentation]. XVIII Congrès National de la SFLS, 19-20 October 2017, Nice Acropolis, France

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Jun 2017, 18 months.

Results were first posted in Jul 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2015
First posted
Nov 17, 2015
StartActual
Nov 18, 2015
Primary completionActual
Jun 14, 2017
CompletionActual
Jan 24, 2018
Results first posted
Jul 13, 2018
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02605954
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 17, 2015
Start date
Nov 18, 2015
Primary completion
Jun 14, 2017
Completion
Jan 24, 2018
Results posted
Jul 13, 2018
Last update
Nov 14, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion